The following represents disclosure information provided by authors of this abstract. The Genitourinary Cancers Symposium Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A safety study of trebananib (AMG 386) and abiraterone in metastatic castration-resistant prostate cancer.
Michelle A. Ojemuyiwa
No relevant relationships to disclose
Fatima H. Karzai
No relevant relationships to disclose
Avani Atul Shah
No relevant relationships to disclose
Marc Robert Theoret
No relevant relationships to disclose
Nancy Harold
No relevant relationships to disclose
Guinevere Chun
No relevant relationships to disclose
Anna Couvillon
No relevant relationships to disclose
Andrea Borghese Apolo
No relevant relationships to disclose
Douglas K. Price
No relevant relationships to disclose
Ravi Amrit Madan
No relevant relationships to disclose
William Douglas Figg
No relevant relationships to disclose
James L. Gulley
No relevant relationships to disclose
William L. Dahut
No relevant relationships to disclose